NEW YORK and LONDON, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ: AKTX ), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today announced that it intends to offer and

Completion of enrollment into COBALT, the Phase II PNH trial of Coversin™ NEW YORK and LONDON , Oct. 11, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically the complement

Plans to start Coversin Phase III in PNH in Q1 2018 NEW YORK and LONDON , Sept. 21, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory

NEW YORK and LONDON , Sept. 19, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, is pleased to announce its Chief Executive Officer Dr. David Horn Solomon and Chief Operations Officer Clive Richardson will present at the Cantor

NEW YORK and LONDON , Aug. 21, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX) is pleased to announce that Dr David Horn Solomon will be appointed as the company’s new chief executive officer (CEO), effective August 28, 2017 . “I am very pleased that David will be joining Akari and that

NEW YORK and LONDON , Aug. 10, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that Clive Richardson , Chief Operations Officer, and Dr. Wynne Weston-Davies , Medical Director, will present at the 37th Annual

NEW YORK and LONDON , June 23, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), a clinical-stage biopharmaceutical company, is presenting a poster today at the 22nd Congress of the European Hematology Association (EHA) in Madrid, Spain containing data for the four patients, to date, who

- Executive Chairman to Continue to Fulfill Interim CEO Duties as Board Commences Executive Search - Data Correction for Fifth Patient in Phase 2 PNH Trial for Coversin NEW YORK & LONDON --(BUSINESS WIRE)--May 30, 2017-- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage

NEW YORK and LONDON, April 27, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX ), an emerging growth, clinical-stage biopharmaceutical company, released today a statement that Edison Investment Research Ltd. has withdrawn its report issued yesterday titled  “Akari’s Coversin matches

-Interim Phase 2 PNH data demonstrate positive response with Coversin™ -Phase 3 PNH program expected to commence in 4Q2017 -Data from preclinical aHUS model demonstrates positive results -New preclinical data demonstrates positive response of Coversin’s combined C5 and LTB4 therapy in skin and eye